Europe ranks second behind the United States in terms of the largest market for diabetes management therapies and products. One reason for the rise of diabetes in Europe is attributed to its aging population, which lends to a higher prevalence of abnormal glucose tolerance in the adult population. In 2010, roughly 33% of the European population as a whole was older than 50 years, a percentage that is expected to surpass 40% by 2030.
Europe ranks second behind the United States in terms of the largest market for diabetes management therapies and products. One reason for the rise of diabetes in Europe is attributed to its aging population, which lends to a higher prevalence of abnormal glucose tolerance in the adult population. In 2010, roughly 33% of the European population as a whole was older than 50 years, a percentage that is expected to surpass 40% by 2030.
Like most global markets, diabetes in Europe is dominated by sales of insulin, test strips and anti-diabetic drugs. Significant growth is expected in novel technologies like continuous blood glucose monitors and integrated pumps/monitors (eventually, “artificial pancreas” products), but the existing market is still very dominated by well established diabetes products.
Source: MedMarket Diligence, LLC; Report #D510.
